Second quarter summary
Phase 1a/b study: positive placebo-controlled safety data for KL1333 and the first evidence of efficacy
Important events second quarter (Apr – Jun 2021)
- Data from the Phase 1a/b clinical study of KL1333 was released and confirmed the safety and pharmacokinetic profile of the drug. In addition, in a cohort of eight patients (six dosed with KL1333, two with placebo), there were signs of efficacy across well-established relevant clinical endpoints including two patient-reported fatigue endpoints and a functional endpoint.
- Extraordinary General Meeting was held on 29 April 2021.
- The directed share issue, approved by the Extraordinary General Meeting, was completed. The Company raised approx. SEK 76 million after deduction of issue costs.
- Annual General Meeting was held on 20 May 2021.
Important events after the reporting period
- The validation study of fatigue as an endpoint, for the KL1333 Phase 2/3 study, was completed.
Financial information
April-June 2021*
- Net revenues: SEK 18,000 (97,000)
- Other operating income: SEK 0,000 (34,000)
- Loss before tax: SEK 30,314,000 (20,312,000)
- Loss per share: SEK 0.08 (0.09)
- Diluted loss per share: SEK 0.08 (0.09)
January-June 2021*
- Net revenues: SEK 18,000 (105,000)
- Other operating income: SEK 0,000 (34,000)
- Loss before tax: SEK 51,770,000 (36,849,000)
- Loss per share: SEK 0.13 (0.18)
- Diluted loss per share: SEK 0.13 (0.18)
* APM Alternative perfomance measures, see definition on page 20.
The complete Interim report is available for download below and through the company’s website www.abliva.com